ID
45474
Beschrijving
Principal Investigator: E. Ann Coleman, University of Arkansas for Medical Sciences Little Rock, Arkansas, USA MeSH: Multiple Myeloma https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000545 We hypothesized that genetic variability in the enzymes/proteins involved in drug metabolism, inflammation, and immune function is a major underlying contributor to mucositis incidence and progression and that, based on this variability we can identify variants that influence risk, and develop a mucositis progression prediction model that improves on existing models by incorporating genetic variability along with clinical factors. Using genome wide association study (GWAS) combined with a pathway candidate gene approach and a modified case-control study method, we investigated the hypothesis in a sample of 1092 patients who received a myeloablative dose of melphalan (MEL) followed by autologous hematopoietic stem cell (ASCT) transplantation as treatment for multiple myeloma and for whom banked blood stem cell samples and clinical data were available.
Link
Trefwoorden
Versies (2)
- 31-10-22 31-10-22 - Simon Heim
- 13-12-22 13-12-22 - Kristina Keller
Houder van rechten
E. Ann Coleman, University of Arkansas for Medical Sciences Little Rock, Arkansas, USA
Geüploaded op
13 december 2022
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
dbGaP phs000545 Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors
Subject ID, age, type of cancer, BMI, body surface area, weight, gender, race, hematocrit, hemoglobin, GFR, creatinine, albumin, c-reactive protein, Melphelan dose, beta-microglobulin, myeloma isotype, mucositis grade, and CMV of participants involved in the "Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants involved in the "Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors" project.
- Subject ID, sample ID, sample source, sample source ID, and sample use variable associated with participants involved in the "Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors" project.
- Subject ID, age, type of cancer, BMI, body surface area, weight, gender, race, hematocrit, hemoglobin, GFR, creatinine, albumin, c-reactive protein, Melphelan dose, beta-microglobulin, myeloma isotype, mucositis grade, and CMV of participants involved in the "Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors" project.
- Subject ID, body site where sample was obtained, histological type of sample, analyte type, and tumor status of sample obtained from participants involved in the "Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors" project.
Similar models
Subject ID, age, type of cancer, BMI, body surface area, weight, gender, race, hematocrit, hemoglobin, GFR, creatinine, albumin, c-reactive protein, Melphelan dose, beta-microglobulin, myeloma isotype, mucositis grade, and CMV of participants involved in the "Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors" project.
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of participants involved in the "Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors" project.
- Subject ID, sample ID, sample source, sample source ID, and sample use variable associated with participants involved in the "Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors" project.
- Subject ID, age, type of cancer, BMI, body surface area, weight, gender, race, hematocrit, hemoglobin, GFR, creatinine, albumin, c-reactive protein, Melphelan dose, beta-microglobulin, myeloma isotype, mucositis grade, and CMV of participants involved in the "Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors" project.
- Subject ID, body site where sample was obtained, histological type of sample, analyte type, and tumor status of sample obtained from participants involved in the "Predicting Chemotherapy-Induced Mucositis with Genetic and Clinical Factors" project.
C2348585 (UMLS CUI [1,2])
C1274040 (UMLS CUI [1,2])
C0022885 (UMLS CUI [1,3])
C1522609 (UMLS CUI [1,4])
C3174092 (UMLS CUI [1,2])
C0021017 (UMLS CUI [1,2])
C3203348 (UMLS CUI [1,2])
C0226875 (UMLS CUI [1,2])
C0521585 (UMLS CUI [1,2])
C0872128 (UMLS CUI [1,3])
C0521585 (UMLS CUI [1,2])
C0872128 (UMLS CUI [1,3])
Geen commentaren